Description of Invention:
The invention provides isolated interleukin-T in human form, along with the methods for isolating the interleukin, and its respective non-IL-2 T-Cell growth factor and antibodies.
T cells play both regulatory and effector functions in human immune responses that are often mediated by interleukins. Interleukins are highly redundant and pleitrophic, controlling a wide range of functions. Abnormalities of interleukin and interleukin receptor systems are observed with a broad array of human diseases, including the forms of leukemia and autoimmune diseases such as rheumatoid arthritis that are caused by human T-cell lymphotropic virus-I. Thus, the invention could be used to treat a disorder associated with immune function, such as cancer, AIDS or other immunodeficiencies, by enhancing the immune system or, in treating an immune disorder, such as graft-versus-host disease, leukemia, lymphoma or an allograft rejection, by suppressing the immune system.
Inventors:
TA Waldmann et al. (NCI)
Patent Status:
DHHS Reference No. E-131-2994/0
Portfolios: Internal Medicine Cancer
Cancer -Therapeutics-Biological Response Modifiers-Growth Factors Cancer -Therapeutics Internal Medicine-Therapeutics
For Additional Information Please Contact: Mojdeh Bahar J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-2950
Email: baharm@mail.nih.gov
Fax: (301) 402-0220
